Articles tagged with Ischemia
A first-in-human study at Cleveland Clinic found that targeting the dentate nucleus with deep brain stimulation was safe and feasible for promoting post-stroke rehabilitation, enabling significant functional improvement in upper extremity hemiparesis. The study's adaptive design allowed for extended treatment duration if patients conti...
Researchers from the University of Tsukuba found that blocking CD300a enhances efferocytosis and ameliorates neuronal deficits after ischemic stroke. This process involves the removal of damaged cells in the brain, reducing inflammation and neurological impairment.
A new locally acting treatment aims to reduce the severity of post-transplant ischemia reperfusion injury (IRI) without affecting the immune system. The treatment targets specific neoepitopes exposed on injured donor organs, reducing the risk of organ rejection and improving transplant outcomes.
Researchers have found a specific protein, circulating fatty acid synthase (cFAS), in the blood that can accurately detect severe peripheral artery disease and narrow the arteries in the legs. The study suggests that cFAS may contribute to plaque formation characteristic of cardiovascular disease.
A study published in Stroke Journal Report found that eating 4-5 peanuts per day lowers the risk of ischemic stroke and cardiovascular disease among Japanese men and women. Peanuts are rich in heart-healthy nutrients that help reduce cardiovascular disease risk factors.
A preclinical study found that age-related decline in two sirtuin enzymes alters mitochondrial dynamics, weakening cardiac contractions in response to ischemia-reperfusion injury. Boosting SIRT1/SIRT3 levels may help protect against such injuries, potentially reducing heart attack complications and deaths.
A new meta-analysis of 19,806 patients with chronic coronary syndromes found a statistically significant 21% relative risk reduction in cardiac death with revascularization plus medical therapy. The study also showed a parallel significant reduction in spontaneous myocardial infarction, but no difference in all-cause death.
A new study reveals that only 32.3% of US patients undergoing PCI for SIHD met ISCHEMIA trial inclusion criteria, while others had high-risk features or negative functional testing. These findings suggest the trial's results may not be representative of real-world interventional practice.
Researchers developed an acellular product, PEP, derived from platelets that heals ischemic wounds by delivering healing messages to cells. The study demonstrates restoration of skin integrity and function in preclinical animal models.
Researchers discovered that farnesyl pyrophosphate, an intermediate in normal cell metabolism, causes rapid and extensive cell death when present at high concentrations outside cells. Inhibition of TRPM2 channels or targeting its metabolic pathway may offer new avenues for reducing stroke damage.
Researchers at Tokyo Medical and Dental University have developed an mRNA delivery system that effectively produces BDNF protein in rat brain to protect neurons from ischemia. The system, known as an mRNA nanomicelle, increases the survival of hippocampal neurons and shows long-term therapeutic benefits.
Researchers developed an exosome-coated stent that heals vascular injury by delivering regenerative stem cell-derived therapy to ischemic tissue. The stent reduces restenosis and promotes endothelial coverage compared to traditional drug-eluting and bare metal stents.
A Phase II clinical trial is being conducted to evaluate the safety and efficacy of MultiStem cellular therapy for treating injured patients with severe hemorrhage. The study aims to mitigate complications resulting from traumatic injuries, including secondary infections and organ failure conditions.
When brain oxygen is low, neurons produce estrogen that activates astrocytes to increase cell signaling, release neuroprotective factors, and clear neurotoxins. Astrocyte activation is critical for brain protection, and researchers have found that neuron-derived estrogen is essential for this process.
The ISCHEMIA trial results show that initial medical therapy is more beneficial than invasive interventions like revascularization in reducing hard outcomes and improving health outcomes for patients with chronic coronary syndromes. The study's findings have significant implications for current guidelines and future clinical practices.
A new study has shown that patients with intermediate left main coronary artery disease are at a higher risk of cardiovascular events compared to those without the condition. The ISCHEMIA trial sub study found no significant difference in outcomes between invasive and conservative strategies for these patients.
A retrospective study found bowel abnormalities in 31% of COVID-19 patients, with thickening and ischemic findings more common in ICU patients. The study suggests that SARS-CoV-2 may play a role in causing bowel or vascular injury, and further research is needed to clarify the cause of these findings.
Cardiologists successfully treated an 80-year-old patient after evaluating data from her Apple Watch, which showed signs of marked ST segment depression. The digital diagnostic aid may prevent myocardial infarctions and save many lives.
People with symptomatic PAD who took rivaroxaban with aspirin after revascularization had a significant reduction in the composite primary endpoint, including acute limb ischemia, major amputation, heart attack, ischemic stroke or cardiovascular death. Rivaroxaban also showed no excess in severe bleeding events.
Patients with abnormal stress test results but clear arteries experience changes in symptoms over time. The study found that disease activity ebbs and flows, with periods of increased symptom severity and absence.
Two NIH-funded studies find that invasive procedures like stenting and surgery provide better symptom relief but not reduced risk for heart attack and death compared to medication and lifestyle changes. The trials followed over 5,000 patients with stable ischemic heart disease for three years.
Researchers found that membrane vesicles derived from human mesenchymal stem cells can stimulate angiogenesis, a key process for treating ischemic tissue damage. The study suggests that these vesicles could be used for cell-free therapy of degenerative diseases such as heart disease, multiple sclerosis, and Alzheimer's disease.
Lylex Pharmaceuticals is developing compounds targeting key enzymes responsible for organ damage, inflammation and rejection after transplant. The lead compound has shown high potency while minimizing toxic effects.
Researchers found that a decrease in CPC counts during an exercise test can predict high risk of heart attack or death over the next three years. Monitoring CPC response to exercise provides more information than nuclear imaging for cardiac ischemia, reducing radiation exposure.
The ISCHEMIA trial found that early revascularization doesn't lower rates of death or heart failure in stable patients, but improves quality of life and reduces spontaneous heart attacks. The study confirms the effectiveness of PCI in relieving angina symptoms.
A recent study found that mitochondrial damage-associated molecular patterns (mtDAMPs) are released by DCD hearts following warm ischemia, correlating with subsequent contractile recovery. The research team aims to investigate the role of mtDAMPs in inflammatory responses and recovery of contractile function in cardiac grafts.
Russian researchers have shown an antioxidant compound called peroxiredoxin to be effective in treating kidney injury in mice by tripling survival rates. The compound may also offer prospects for longer kidney transplant storage and improved treatment options for ischemia-reperfusion syndrome.
A recent study found that boosting levels of tiny RNA miR322 can reduce heart muscle death by 40% after a heart attack. The research suggests that miR322 regulates the enzyme FBXW7, which tags cells for elimination, and its overexpression can protect the heart from damage.
A new silicon chip system allows researchers to examine the functional effects of drugs on lab-grown human heart muscle cells. The platform, which includes electrodes to stimulate and measure electrical activity, helps determine how treatments affect heart function and conduction velocity in ischemic conditions.
The American Heart Association has released new guidelines for diagnosing and treating critical limb ischemia, a condition that affects an estimated 12 million Americans. The guidelines aim to improve the precision and quality of critical limb ischemia management through non-invasive techniques and devices.
A study by the American Heart Association found that less-invasive leg artery procedures are as effective as open surgery in preventing amputations and improving survival rates. Patients who received endovascular procedures first had longer periods of amputation-free survival compared to those treated with open surgery.
A novel non-hyperemic pressure ratio (NHPR) index, combined with fractional flow reserve (FFR), accurately predicts percutaneous coronary intervention (PCI) success. The study found a significant linear correlation between NHPR and FFR, with a Pd/Pa value of <0.90 demonstrating excellent diagnostic performance against FFR.
Researchers at MGH found that mitochondrial permeability determines the impact of autophagy on lifespan, with low levels required for health benefits. Elevated autophagy can be detrimental due to excessive opening of the mitochondrial permeability transition pore.
Researchers investigate opioid receptors' effect on cardioprotection against coronary disease and find that certain subtypes have a special role in adapting to oxygen lack. The study suggests new targets for developing ischemia prevention drugs, with promising results.
Diabetes mellitus increases risk of stable ischemic heart disease, with trial data showing no benefit from nuclear stress tests or cardiac computed tomography. Revascularization for SIHD also does not reduce mortality or myocardial infarction rates in diabetic patients without symptoms.
Scientists at MCG are studying a new treatment target for retinal damage, characterized by blood vessel disruption leading to vision loss. They believe the key lies in arginase 1, an enzyme that helps regulate inflammation, which can be either damaging or reparative.
A multi-site randomized controlled trial is enrolling patients with critical limb ischemia to compare treatment efficacy, functional outcomes, cost effectiveness, and quality of life. The BEST-CLI Trial seeks to overcome treatment bias by involving multidisciplinary CLI teams at participating sites.
The article discusses how reperfusion injury amplifies cell damage after tissue perfusion. Calcium handling mechanisms, including Ca2+ ion elevation, predispose patients to mitochondrial failure, hyper-contracture, and proteolysis.
A Temple-led research team finds blocking GRK2 localization to mitochondria protects heart cells from ischemic injury and death. The study also reveals that mitochondrial GRK2 pooling is associated with impaired cardiac metabolism and increased heart cell death.
Researchers identified microRNA-668 as a key player in protecting kidney cells from damage caused by acute kidney injury. By upregulating this microRNA, the protective pathway can prevent most of the damage and allow cells to function ideally until blood and oxygen are restored.
Scientists discover enzyme arginase 1 plays protective role in retinal health by suppressing inflammation and promoting recovery. Administering pegylated arginase 1 reduces inflammation and subsequent damage following reperfusion injury, offering potential new treatment for neurovascular injury.
Researchers found that very low troponin levels can rule out stress-inducible ischemia, allowing doctors to avoid routine stress testing. This could reduce healthcare costs and radiation exposure by triaging individuals with stable CAD before performing stress tests.
A recent study found that young plasma has a protective effect on liver damage caused by ischemia reperfusion injury in experimental animals. The study's results demonstrate the therapeutic potential of blood from young animals to prevent age-related phenomena.
A new study reveals that protein galectin-1 has anti-inflammatory properties capable of minimizing damage to kidney cells by hypoxia and reperfusion, common processes in transplants. Galectin-1 may provide an alternative to corticosteroids for ischemia-reperfusion injury.
Researchers found that juvenile pigs' mucosal environment can stimulate repair of intestinal injuries in newborn piglets. The study aims to understand why humans and other young animals have trouble repairing these injuries, with potential implications for treatments.
Researchers found that treatments restoring blood flow to the lower limbs of people with critical limb ischemia can lead to longer survival and reduced healthcare costs compared to amputation. The study analyzed Medicare records of over 72,000 patients diagnosed with primary critical limb ischemia between 2010 and 2015.
A study published in Radiology found that cardiac hybrid imaging, combining CT and nuclear stress testing, is an excellent long-term predictor of adverse cardiac events. The imaging approach helps identify stenosis and perfusion, providing critical information for treatment decisions.
Research suggests that moderate doses of alcohol activate the ALDH2 enzyme, which helps protect heart cells from damage. The study found that hearts exposed to ethanol before ischemia-reperfusion injury showed reduced cell death compared to control groups.
Researchers compared mouse and human blood vessels using three-dimensional imaging, revealing that mice have a more robust vascular structure against lower limb ischemia. The inferior gluteal artery in mice extends further than in humans, allowing for better bypassing of obstructions.
Research highlights the importance of preserving healthy kidney tissue and minimizing ischemia time in partial nephrectomy to prevent chronic kidney disease. Minimally invasive surgery is also shown to offer therapeutic scope without compromising oncological outcomes.
Researchers studying nervous system adaptation to ischemic damage hope to develop effective therapeutic strategies by understanding how neural networks function under stress. They have developed methods for modeling different phases of ischemia and studied the features of neural network operation under such effects.
In this study, scientists analyzed NO production in brain tissue of rats with simulated ischemia. NO levels decreased up to 2-3 times within 5 hours after stroke signs appeared, lasting for 24 and 72 hours.
A study found that many discarded kidney organs can be suitable for transplantation if certain steps are taken to limit damage following donation. The use of these organs could be increased by limiting cold ischemia times.
Researchers at MUSC find that adding vitamin D to hypothermia and N-acetylcysteine treatment improves sensorimotor function, working memory, and reduces brain injury volume in male newborns. Vitamin D deficiency is prevalent in both males and females, highlighting the need for sex-based treatment approaches.
Researchers developed a system to deliver growth factors to stem cells, enabling their survival and differentiation into new blood vessels. This approach successfully restored blood supply and rescued muscle tissue in mouse models of ischemia.
Researchers have developed a method using 3D-printed patches infused with cells that offer a promising new approach to growing healthy blood vessels. The patches with pre-organized structure demonstrated improved results in reducing ischemia, while those without organization resulted in a disorganized network.
Researchers developed a technique using multimodal autofluorescence and light scattering to evaluate kidney function after ischemic injury. The study suggests that variations in tissue microstructure, fluorophore emission, and blood absorption spectral characteristics contribute to the behavior of recorded signals.
Researchers have discovered that altered immune cells activated by placental ischemia can exacerbate preeclampsia symptoms. However, deleting these cells in animal models of the condition reduces hypertension, inflammation, and fetal growth restriction.
Researchers identify that cardiac muscle cells both destroy and create new mitochondria in response to ischemia/reperfusion injury, which can cause long-term effects or fatal heart failure. This discovery may lead to the development of new treatments to speed up healing from open-heart surgery.
A blood test for high-sensitivity troponin T can identify patients with heart damage after non-cardiac surgery, allowing for timely treatment to prevent deaths. The test showed that approximately 18% of patients sustain a heart injury after surgery, which may account for up to 1 in 4 deaths in the first 30 days.